Now Reading: US FDA issues warning letter to Aurobindo Pharma unit
-
01
US FDA issues warning letter to Aurobindo Pharma unit
The US Food and Drug Administration has issued a warning letter to Unit I of Eugia Pharma Specialities, a subsidiary of Aurobindo Pharma near Hyderabad. The action follows four observations from an…
The Story in Brief
The US Food and Drug Administration has issued a warning letter to Unit I of Eugia Pharma Specialities, a subsidiary of Aurobindo Pharma near Hyderabad. The action follows four observations from an inspection in February and an Official Action Indicated (OAI) status in May.
Aurobindo Pharma said on Friday (August 14) the letter does not affect existing US supplies. The unit contributes about 2% of group revenue. Shares fell 1.25% to Rs 1,636.20 on BSE, recovering from early losses.
The Indian Opinion
The warning letter adds to the long list of US FDA actions against Indian pharma units. It is easy to jump to fears of a ban or revenue loss, but the company insists existing supplies are safe. Indian drugmakers often face such letters without catastrophic outcomes. The real test will be whether this affects future approvals or triggers a wider compliance review at Aurobindo's other facilities. Watch for the company's next regulatory filing on corrective steps.
Source: thehindu.com
This story was synthesised by AI from the source linked above.
